The antimicrobial propeptide hCAP-18 plasma levels in neutropenia of various aetiologies: a prospective study
- PMID: 26119962
- PMCID: PMC4484407
- DOI: 10.1038/srep11685
The antimicrobial propeptide hCAP-18 plasma levels in neutropenia of various aetiologies: a prospective study
Abstract
The underlying cause of neutropenia may be difficult to determine due to similar clinical presentation in many neutropenic conditions. The neutrophil protein hCAP-18 (pro-LL-37) is a major component of neutrophil secondary granules and in this prospective study we assessed the use of hCAP-18 levels in blood plasma for differential diagnosis of neutropenic patients (n = 133) of various aetiologies. Plasma levels of hCAP-18 were determined using immunoblot and ELISA. Patients with severe congenital neutropenia (n = 23) presented with the lowest levels of plasma hCAP-18 and differential diagnostic accuracy revealed high sensitivity (100%) and specificity (98.8%) for hCAP-18 ELISA. The correlation coefficient of the hCAP-18 ELISA versus immunoblotting was (R = 0.831) and that of the peptide LL-37 ELISA versus immunoblotting was (R = 0.405) (P < 0.001). Plasma hCAP-18 levels thus displayed high diagnostic value in differential diagnosis of chronic neutropenia. Neutropenic patients with Shwachman-Diamond syndrome, Barth syndrome, Cohen syndrome, acute myeloid leukaemia and specific granule deficiency presented with reduced plasma hCAP-18 levels as well. The blood plasma level of hCAP-18 was thus low in conditions in which the neutrophil antibacterial propeptide hCAP-18 is deficient, i.e. severe congenital neutropenia and neutrophil-specific granule deficiency, and in conditions in which bone marrow myelopoiesis is negatively affected.
Conflict of interest statement
M.L-A.A., G.C., K.L-A.P. are inventors in a patent (# 7591997) owned by the company Mabtech (Sweden) "Method for determining the susceptibility of a subject to infection". Mabtech had no part in initiating the present study, had no influence on study design, data collection and analysis of data, writing the report or in the decision to submit this report for publication. The company has no part in funding of this study. The other authors (T.U.M., N.B., Y.Y., J.M.T.K.) have no conflicts of interest to declare.
Figures




Similar articles
-
Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.Health Technol Assess. 2022 Oct;26(44):1-310. doi: 10.3310/ZUCE8371. Health Technol Assess. 2022. PMID: 36321689 Free PMC article.
-
Antioxidants for female subfertility.Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD007807. doi: 10.1002/14651858.CD007807.pub4. Cochrane Database Syst Rev. 2020. PMID: 32851663 Free PMC article.
-
Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.Health Technol Assess. 2024 Oct;28(73):1-230. doi: 10.3310/YAPL9347. Health Technol Assess. 2024. PMID: 39487661 Free PMC article.
-
Antioxidants for female subfertility.Cochrane Database Syst Rev. 2017 Jul 28;7(7):CD007807. doi: 10.1002/14651858.CD007807.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Aug 27;8:CD007807. doi: 10.1002/14651858.CD007807.pub4. PMID: 28752910 Free PMC article. Updated. Review.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article. Review.
Cited by
-
Cinobufagin Modulates Human Innate Immune Responses and Triggers Antibacterial Activity.PLoS One. 2016 Aug 16;11(8):e0160734. doi: 10.1371/journal.pone.0160734. eCollection 2016. PLoS One. 2016. PMID: 27529866 Free PMC article.
-
A Novel CEBPE Variant Causes Severe Infections and Profound Neutropenia.J Clin Immunol. 2022 Oct;42(7):1434-1450. doi: 10.1007/s10875-022-01304-7. Epub 2022 Jun 20. J Clin Immunol. 2022. PMID: 35726044
-
A VPS13B mutation in Cohen syndrome presented with petechiae: An unusual presentation.Clin Case Rep. 2021 Jul 23;9(7):e04492. doi: 10.1002/ccr3.4492. eCollection 2021 Jul. Clin Case Rep. 2021. PMID: 34322253 Free PMC article.
-
Statins influence epithelial expression of the anti-microbial peptide LL-37/hCAP-18 independently of the mevalonate pathway.Clin Exp Immunol. 2019 Feb;195(2):265-276. doi: 10.1111/cei.13217. Epub 2018 Oct 11. Clin Exp Immunol. 2019. PMID: 30216432 Free PMC article.
-
Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2019 Jan 25;14:321-330. doi: 10.2147/COPD.S185602. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 30774329 Free PMC article.
References
-
- Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6, 173–182 (2006). - PubMed
-
- Boxer L. A. How to approach neutropenia. Hematology Am Soc Hematol Educ Program 2012, 174–182 (2012). - PubMed
-
- Niemeyer C. M. & Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2011, 84–89 (2011). - PubMed
-
- Walkovich K. & Boxer L. A. How to approach neutropenia in childhood. Pediatr Rev 34, 173 (2013). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources